Targeting Notch and Hedgehog Embryonic Signaling Pathways Has Potent Anti-Tumor Activity in Myeloma and Is Effective in Myeloma Bone Disease.

被引：0
|
作者：
Schwarzer, Rolf [1 ]
Schuenemann, Nicole [1 ]
Wong, David M. [2 ]
Bogen, Bjarne [3 ,4 ]
Bommert, Kurt [5 ]
Doerken, Bernd [1 ]
Manz, Rudolf [2 ]
Jundt, Franziska [1 ]
机构：
[1] Univ Med Berlin, Charite, Dept Hematol & Oncol, Berlin, Germany
[2] Med Univ Lubeck, Inst Syst Inflammat Res, D-23538 Lubeck, Germany
[3] Univ Oslo, Dept Immunol & Transfus Med, Ctr Immune Regulat, Oslo, Norway
[4] Oslo Univ Hosp, Oslo, Norway
[5] Univ Wurzburg, Med Ctr, D-97070 Wurzburg, Germany
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.2938.2938
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2938
引用
收藏
页数：2
相关论文
共 46 条
  • [41] Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding
    van der Horst, Hilma J.
    Overdijk, Marije B.
    Breij, Esther C. W.
    Chamuleau, Martine
    Lokhorst, Henk M.
    Mutis, Tuna
    [J]. BLOOD, 2017, 130
  • [42] Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma
    Siu, Ka Tat
    Ramachandran, Janani
    Yee, Andrew J.
    Eda, Homare
    Santo, Loredana
    O'Donnell, Elizabeth K.
    Panaroni, Cristina
    Mertz, Jennifer
    Sims, Robert J.
    Cooper, Michael
    Raje, Noopur
    [J]. BLOOD, 2016, 128 (22)
  • [43] The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma
    Ng, Patrick P.
    Aaron, Wade
    Callihan, Evan
    Hemmati, Golzar
    Law, Che-Leung
    Azab, Abdel Kareem
    Sun, Laura
    [J]. BLOOD, 2021, 138
  • [44] Oral administration of the opium alkaloid noscapine (NOS) exhibits potent anti-tumor activity against non-Hodgkin's lymphomas and myeloma cell lines in vitro and in vivo in SCID-beige murine xenograft models.
    O'Connor, O
    Mastrella, J
    Smith, E
    Toner, L
    Auerbach, A
    Leonard, JP
    [J]. BLOOD, 2005, 106 (11) : 682A - 682A
  • [45] Imaging tumor burden by [18F]FDG-PET and osteoblast activity by [99mTc]MDP-SPECT/CT in the 5TGM1 mouse model of myeloma bone disease.
    Oyajobi, BO
    Goins, B
    Gupta, A
    Zavaleta, C
    Grubbs, B
    Wideman, C
    Wang, Z
    Garrett, IR
    Phillips, W
    Mundy, GR
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S212 - S212
  • [46] SGN-CEACAM5C/SAR445953, a novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5, has potent anti-tumor activity in CRC, PDAC, GC and lung cancer tumor models
    Baudat, Yves
    Nicolazzi, Celine
    Sigurjonsson, Johann Petur
    Amara, Celine
    Clarke, Astrid
    Lyski, Ryan
    Meyer, Dave
    Fantin, Valeria
    Chiron, Marielle
    Decary, Stephanie
    [J]. CANCER RESEARCH, 2024, 84 (06)
12345